Literature DB >> 25880364

A unified model for bone-renal mineral and energy metabolism.

Peter S Rowe1.   

Abstract

The beginning of the millennium saw the discovery of a new bone-matrix protein, Matrix Extracellular PhosphoglycoprotEin (MEPE) and an associated C-terminal motif called ASARM. This motif and other distinguishing features occur in a group of proteins called SIBLINGs. These proteins include dentin matrix protein 1 (DMP1), osteopontin, dentin-sialophosphoprotein (DSPP), statherin, bone sialoprotein (BSP) and MEPE. MEPE, DMP1 and ASARM-motifs regulate expression of a phosphate regulating cytokine FGF23. Further, a trimeric interaction between phosphate regulating endopeptidase homolog X-linked (PHEX), DMP1, and α5β3-integrin that occurs on the plasma-membrane of the osteocyte mediates FGF23 regulation (FAP pathway). ASARM-peptides competitively inhibit the trimeric complex and increase FGF23. A second pathway involves specialized structures, matrix vesicles pathway (MVP). This review will discuss the FAP and MVP pathways and present a unified model for mineral and energy metabolism.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25880364      PMCID: PMC4470732          DOI: 10.1016/j.coph.2015.03.006

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  79 in total

Review 1.  Return of the secretory kidney.

Authors:  Jared J Grantham; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2002-01

2.  FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.

Authors:  Victoria Shalhoub; Edward M Shatzen; Sabrina C Ward; James Davis; Jennitte Stevens; Vivian Bi; Lisa Renshaw; Nessa Hawkins; Wei Wang; Ching Chen; Mei-Mei Tsai; Russell C Cattley; Thomas J Wronski; Xuechen Xia; Xiaodong Li; Charles Henley; Michael Eschenberg; William G Richards
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

3.  Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.

Authors:  Thomas O Carpenter; Erik A Imel; Mary D Ruppe; Thomas J Weber; Mark A Klausner; Margaret M Wooddell; Tetsuyoshi Kawakami; Takahiro Ito; Xiaoping Zhang; Jeffrey Humphrey; Karl L Insogna; Munro Peacock
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

4.  Overexpression of the insulin receptor inhibitor PC-1/ENPP1 induces insulin resistance and hyperglycemia.

Authors:  Betty A Maddux; Yow-Ning Chang; Domenico Accili; Owen P McGuinness; Jack F Youngren; Ira D Goldfine
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-11-08       Impact factor: 4.310

5.  Reply to Lrp5 regulation of bone mass and gut serotonin synthesis.

Authors:  Yajun Cui; Paul J Niziolek; Bryan T MacDonald; Natalia Alenina; Susann Matthes; Christina M Jacobsen; Ronald A Conlon; Robert Brommage; David R Powell; Xi He; Michael Bader; Bart O Williams; Matthew L Warman; Alexander G Robling
Journal:  Nat Med       Date:  2014-11       Impact factor: 53.440

6.  The association of FGF23 levels in obese adolescents with insulin sensitivity.

Authors:  Malgorzata Wojcik; Dominika Janus; Katarzyna Dolezal-Oltarzewska; Dorota Drozdz; Krystyna Sztefko; Jerzy B Starzyk
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

7.  Evolution of metabolic and functional derangements of pancreatic islets in phosphate depletion.

Authors:  E Levi; G Z Fadda; C Ozbasli; S G Massry
Journal:  Endocrinology       Date:  1992-11       Impact factor: 4.736

8.  Variants of insulin-signaling inhibitor genes in type 2 diabetes and related metabolic abnormalities.

Authors:  Carlo de Lorenzo; Annalisa Greco; Teresa Vanessa Fiorentino; Gaia Chiara Mannino; Marta Letizia Hribal
Journal:  Int J Genomics       Date:  2013-05-23       Impact factor: 2.326

Review 9.  The contribution of bone to whole-organism physiology.

Authors:  Gérard Karsenty; Mathieu Ferron
Journal:  Nature       Date:  2012-01-18       Impact factor: 69.504

10.  Lrp5 functions in bone to regulate bone mass.

Authors:  Yajun Cui; Paul J Niziolek; Bryan T MacDonald; Cassandra R Zylstra; Natalia Alenina; Daniel R Robinson; Zhendong Zhong; Susann Matthes; Christina M Jacobsen; Ronald A Conlon; Robert Brommage; Qingyun Liu; Faika Mseeh; David R Powell; Qi M Yang; Brian Zambrowicz; Han Gerrits; Jan A Gossen; Xi He; Michael Bader; Bart O Williams; Matthew L Warman; Alexander G Robling
Journal:  Nat Med       Date:  2011-05-22       Impact factor: 53.440

View more
  6 in total

1.  Acute Adaption to Oral or Intravenous Phosphate Requires Parathyroid Hormone.

Authors:  Linto Thomas; Carla Bettoni; Thomas Knöpfel; Nati Hernando; Jürg Biber; Carsten A Wagner
Journal:  J Am Soc Nephrol       Date:  2016-10-06       Impact factor: 10.121

2.  Cancer-Osteoblast Interaction Reduces Sost Expression in Osteoblasts and Up-Regulates lncRNA MALAT1 in Prostate Cancer.

Authors:  Aimy Sebastian; Nicholas R Hum; Bryan D Hudson; Gabriela G Loots
Journal:  Microarrays (Basel)       Date:  2015-10-29

3.  Inhibitor of ppGalNAc-T3-mediated O-glycosylation blocks cancer cell invasiveness and lowers FGF23 levels.

Authors:  Lina Song; Adam D Linstedt
Journal:  Elife       Date:  2017-03-31       Impact factor: 8.140

4.  Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.

Authors:  Christian Callebaut; Yang Liu; Darius Babusis; Adrian Ray; Michael Miller; Kathryn Kitrinos
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

5.  Elevated serum levels of bone sialoprotein during ICU treatment predict long-term mortality in critically ill patients.

Authors:  Mark Luedde; Sanchari Roy; Hans-Joerg Hippe; David Vargas Cardenas; Martina Spehlmann; Mihael Vucur; Pia Hoening; Sven Loosen; Norbert Frey; Christian Trautwein; Tom Luedde; Alexander Koch; Frank Tacke; Christoph Roderburg
Journal:  Sci Rep       Date:  2018-06-27       Impact factor: 4.379

6.  PHEXL222P Mutation Increases Phex Expression in a New ENU Mouse Model for XLH Disease.

Authors:  Carole El Hakam; Alexis Parenté; Fabienne Baraige; Laetitia Magnol; Lionel Forestier; Florent Di Meo; Véronique Blanquet
Journal:  Genes (Basel)       Date:  2022-07-28       Impact factor: 4.141

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.